Geron to Host a Virtual Investor Event in November

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will hold a virtual investor event on November 9 at 4:00 p.m. ET. The event will address unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis, focusing on the potential of imetelstat, Geron's first-in-class telomerase inhibitor. Attendees will hear about expansion opportunities for imetelstat and can participate in a live Q&A with experts, including Dr. Swaminathan Iyer and Dr. John Mascarenhas. A webcast will be available on Geron's Investor Relations page, archived for 30 days.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) will host a virtual investor event on November 9 at 4:00 p.m. ET. Topics to be covered at the event, include:

• The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential of imetelstat, Geron’s first-in-class telomerase inhibitor.
• Expansion opportunities for imetelstat into new indications and in combination with other drugs.
• A live physician panel discussion and question-and-answer session with:
  • Dr. Swaminathan Iyer, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Dr. John Mascarenhas, Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
  • Prof. Uwe Platzbecker, Director, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, University Hospital, Leipzig, Germany

A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in myeloid hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005443/en/

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What is the date and time of Geron Corporation's investor event?

Geron Corporation's investor event is scheduled for November 9 at 4:00 p.m. ET.

What topics will Geron Corporation cover during the investor event?

The event will discuss unmet medical needs in lower risk myelodysplastic syndromes, the potential of imetelstat, and expansion opportunities for the drug.

Who will be participating in the live Q&A at Geron's investor event?

The live Q&A will feature Dr. Swaminathan Iyer, Dr. John Mascarenhas, and Prof. Uwe Platzbecker.

Where can I access the webcast of Geron Corporation's investor event?

The webcast will be available on Geron's Investor Relations section and archived for 30 days post-event.

What is imetelstat and its significance for Geron Corporation?

Imetelstat is Geron's first-in-class telomerase inhibitor, targeted for treating myeloid hematologic malignancies.